How do life sciences companies maintain the data integrity of their GxP systems on a lasting basis in line with ALCOA+ principles?

Data integrity rarely breaks down on the technology in practice, but on the sequence. Whoever configures audit trails and validates systems first, without knowing the critical data flows, often safeguards the wrong places: a cleanly validated LIMS is of little use if the release-relevant evaluation still happens in an unprotected spreadsheet. That is why robust Data Integrity Assurance begins with the risk-based criticality analysis per ICH Q9 and the gap analysis against ALCOA+ and PIC/S PI 041. Only then do audit trail review, procedures and validation follow. This sequence shifts the effort to where it prevents the most findings, instead of spreading it evenly across non-critical and critical systems.

In the remediation case, the bottleneck is a different one: after an inspection finding, the individual symptom is corrected under time pressure, the one missing audit trail, the one shared account. Without root cause analysis, the underlying gap in procedures and the system landscape remains open, and the deficiency returns in the follow-up audit. That is why we set up the corrective actions through the CAPA system, with documented evidence of effectiveness, and embed the changed behaviour in SOPs and role-specific training. This turns a one-off reaction into a system that withstands the next inspection under Annex 11 and 21 CFR Part 11.